Holen Sie sich die Stockscreener-App
131.62
2.12%
2.73
Handel nachbörslich:
131.62
Schlusskurs vom Vortag:
$128.89
Offen:
$129.99
24-Stunden-Volumen:
1.06M
Relative Volume:
1.06
Marktkapitalisierung:
$13.05B
Einnahmen:
$2.41B
Nettoeinkommen (Verlust:
$305.80M
KGV:
44.62
EPS:
2.95
Netto-Cashflow:
$492.20M
1W Leistung:
+2.48%
1M Leistung:
-1.38%
6M Leistung:
+12.62%
1J Leistung:
-12.66%
1-Tages-Spanne:
$129.85
$131.79
1-Wochen-Bereich:
$123.67
$131.79
52-Wochen-Spanne:
$84.23
$154.87
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Vergleichen Sie NBIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
131.62 | 12.78B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
152.44 | 66.38B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 46.20B | 29.96B | 957.25M | 5.31B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.69 | 42.99B | 14.26B | 1.98B | 0 | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 19.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.72 | 13.63B | 2.99B | 1.21B | 1.13B | 25.06 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Neurocrine at Canaccord Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
Stronger-Than-Expected Q2 Results Could Be a Game Changer for Neurocrine Biosciences (NBIX) - simplywall.st
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2025 Earnings Call Transcript - MSN
Neurological Disorder Drugs Market Set to Witness Significant - openPR.com
Will Neurocrine Biosciences Inc. bounce back from current supportWatchlist Summary for Active Day Traders - Newser
Top chart patterns to watch in Neurocrine Biosciences Inc.5-Year Price Trend Summary and Analysis - Newser
What’s next for Neurocrine Biosciences Inc. stock priceFree Daily Growth Stock Pick Reports - Newser
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025 - GlobeNewswire Inc.
Neurocrine Biosciences shares rise 3.11% after-hours following Nxera Pharma's obesity pipeline progress. - AInvest
Neurocrine Biosciences Director Gorman Buys, Sells 106,322 Shares on 8/7/2025 - AInvest
This Neurocrine Biosciences Insider Reduced Their Stake By 28% - 富途牛牛
Neurocrine CEO and IR Chief to Share Latest Growth Strategy at Major Biotech Conference - Stock Titan
Neurocrine Biosciences shares fall 1.10% intraday as Nxera Pharma launches obesity drug pipeline. - AInvest
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail
Tardive Dyskinesia Drugs Market Exclusive Report with Detailed - openPR.com
Guggenheim Boosts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $175.00 - MarketBeat
Trendlines Converge — Decision Point for Neurocrine Biosciences Inc.Secure Capital Picks With Upside Potential Tracked - metal.it
CRENESSITY's Breakout Launch Might Change the Case for Investing in Neurocrine Biosciences (NBIX) - simplywall.st
What drives Neurocrine Biosciences Inc. stock priceUnlock powerful trading alerts for success - Jammu Links News
Is Neurocrine Biosciences Inc. a growth stock or a value stockTremendous wealth creation - Jammu Links News
Neurocrine Biosciences Inc. Stock Analysis and ForecastRapid portfolio appreciation - Jammu Links News
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $144.00 at Royal Bank Of Canada - MarketBeat
How does Neurocrine Biosciences Inc. generate profit in a changing economyMaximize portfolio value with smart investment plans - Jammu Links News
How many analysts rate Neurocrine Biosciences Inc. as a “Buy”Dynamic growth stocks - Jammu Links News
What is the risk reward ratio of investing in Neurocrine Biosciences Inc. stockAchieve consistent profits with expert advice - Jammu Links News
What makes Neurocrine Biosciences Inc. stock price move sharplyStay ahead with daily market updates - Jammu Links News
What is the dividend policy of Neurocrine Biosciences Inc. stockAchieve rapid financial growth with expert picks - Jammu Links News
Contradictions in Focus: Analyzing INGREZZA and Crinecerfont's Market Dynamics and Pricing Strategies - AInvest
How volatile is Neurocrine Biosciences Inc. stock compared to the marketExplosive earnings growth - Jammu Links News
Is Neurocrine Biosciences Inc. stock overvalued or undervaluedGet daily updates on promising stocks - Jammu Links News
What institutional investors are buying Neurocrine Biosciences Inc. stockUnlock real-time stock alerts for quick profits - Jammu Links News
Neurocrine Biosciences chief commercial officer sells $115,940 in stock - MSN
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2025 Earnings Call Transcript - Insider Monkey
Research Alert: CFRA Retains Hold Opinion On Shares Of Neurocrine Biosciences, Inc. - 富途牛牛
Neurocrine's Promising Outlook: Strong Crenessity Sales and Strategic Ingrezza Adjustments Drive Buy Rating. - AInvest
Guggenheim Raises Price Target for Neurocrine Biosciences, Maintains "Buy" Rating - AInvest
Neurocrine Biosciences’ Promising MDD Treatment Study: Key Insights for Investors - TipRanks
Neurocrine Biosciences: Guggenheim raises PT to $175, maintains Buy rating. - AInvest
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $140 to $200 - 富途牛牛
Neurocrine Biosciences Second Quarter 2025 Earnings: Beats Expectations - simplywall.st
Neurocrine (NBIX) Q2 Revenue Jumps 17% - Nasdaq
Neurocrine Biosciences’ Earnings Call Highlights Growth - TipRanks
Neurocrine Biosciences: JP Morgan Maintains Neutral, PT Raised to $145. - AInvest
The Analyst Verdict: Neurocrine Biosciences In The Eyes Of 17 Experts - 富途牛牛
Guggenheim raises Neurocrine Bio. stock price target on strong Ingrezza sales - Investing.com Canada
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $141 to $192 - 富途牛牛
Prime Medicine is selling $125M in stock; Nuvectis stops work on ovarian cancer drug - Endpoints News
Neurocrine Bio. price target raised to $145 from $140 at Mizuho - Investing.com Canada
Neurocrine Biosciences: Wedbush raises PT to $141, maintains Outperform rating. - AInvest
Neurocrine Biosciences Positioned For Growth And New Potential Blockbusters (NASDAQ:NBIX) - Seeking Alpha
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):